Bio Roundup: Lung Cancer Questions, Migraine Races, HIV Battle & More
Xconomy
FEBRUARY 9, 2018
Second, it still hasn’t proven whether the combination helps patients more than its immunotherapy drug nivolumab (Opdivo) used alone. Added up, the highly anticipated data led to a small stock dip and lots. First, Bristol changed the trial’s structure midstream. More results are still to come.
58 
Let's personalize your content